Inovio Biomedical (INO) Announces Positive Results From H1N1 Trial
More News related to INO
- NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
- Unusual 11 Mid-Day Movers 11/20: GGR, TTIL, INO, NLST Higher; EFUT, HAWK, ADCT, DHI Lower
- Morning Movers 11/20: TTIL, INO, SRLS, NLST, ZUMZ Higher; EFUT, BOFL, HFFC, ADCT, AMFI Lower
- Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies
- Inovio Biomedical Universal DNA Vaccine for Chikungunya Virus Demonstrates Protective Antibody Responses in Monkey Model
Inovio Biomedical Corporation (NYSE: INO) announced that the company's SynCon H1N1 influenza DNA vaccines achieved protection against current circulating swine origin influenza A/H1N1 viruses in animal studies.
The company had previously reported interim data from an ongoing study in a pig model in which the SynCon based H1N1 vaccines achieved hemagglutination inhibition (HI) titers above the protection threshold in 100% of the vaccinated animals against the swine influenza virus (A/Iowa/35233/1999). In a continuation of this study, Inovio investigators tested the immune sera for responses against a virus isolated from the current circulating strain of swine origin influenza A/H1N1 (Swine A/Mexico/InDRE4487/2009). All the animals immunized with the SynCon™ H1N1 vaccine developed HI titers exceeding the 1:40 level commonly associated with protective immunity.
In a second study, the investigators immunized mice with the NP and m2E components of the vaccine and challenged these animals with a second related strain also isolated from the current circulating influenza A/H1N1 (A/Canada/AB/RV1532/2009). While all mice showed effects of virus challenge as judged by significant weight loss, the vaccinated mice recovered from virus infection-induced morbidity significantly faster compared to the non-immunized control animals.
In a previous study, the Inovio team demonstrated that mice immunized with Inovio’s SynCon™ H1N1 DNA vaccine provided 100% protection in a lethal challenge study against an unmatched H1N1 virus that caused the 1918 Spanish flu, which killed over 40 million people worldwide.
Related Categories
FDAStocks Mentioned
+0.33Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Buy INO
Francorp on Aug 2, 2009 01:29 AMI like INO a lot going into this week, (8/03/09) Strong bullish trend for INO to cross into $3 pps again.